Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Blood Stem Cells in Severe Covid-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose clinical and laboratory test results have a positive diagnosis of Covid-19.~* Patients who are willing to participate as subjects in the study by signing the informed content.~* Diagnosed with severe pneumonia of COVID: respiratory distress, RR \>30 times/min; resting oxygen saturation of 90% or less; arterial partial pressure of oxygen / oxygen concentration ≤300mmHg; Pulmonary infiltration more than 50% in 24 to 48 hours~* SARS-CoV-2 nucleic acid test was positive.~Exclusion Criteria:~* History of drug reactions or allergies~* Pneumonia caused by bacteria, Mycoplasma, Chlamydia, Legionella, fungi, or other viruses~* Airway obstruction due to lung cancer or unknown factors~* Carcinoid syndrome~* History of epilepsy and long-term use of anticonvulsant drugs during the last 3 years~* History of long-term use of immunosuppressive drugs~* History of chronic respiratory illness that requires long-term oxygen therapy~* The patient is on blood or peritoneal dialysis~* Creatinine clearance \<15 ml / min~* Moderate to severe liver disease (Child-Pugh score\> 12)~* History of deep vein thrombosis (DVT) or pulmonary embolism over the past 3 years~* Being under ECMO or high-frequency oscillatory ventilation support~* Diagnostic of HIV, hepatitis B, and syphilis~* Pregnant or lactating women~* Lack of consciousness and inability to provide informed consent by the patient

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Menstrual blood stem cell secretome group (Type: EXPERIMENTAL): Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment
- Control group (Type: PLACEBO_COMPARATOR): Intravenous saline injection (Placebo)+Routine treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).